CRSP shorts build steadily as analysts wait for November data

The Street is constructive but not closing the gap to the current price. All coverage sits at buy or outperform, with no sell ratings on record, and targets cluster between $80 and $110 against a stock trading near $52. Citigroup raised its target to $88 following the August earnings print, but the last formal consensus update was late August and the data is now 49 days old. The most cautious voice on the register is Bernstein, which carries a Market Perform and a $56 target, roughly where the stock was trading when that target was set in May. Bulls point to CTX310's 12-month data showing a mean 78.6% reduction in ANGPTL3 at the highest tested dose, no new safety signals, and management's expectation that Casgevy reaches more than $1 billion in global sales by 2030. Bears counter that the cohorts are small, durability across the broader platform remains unproven, and the company's dependence on Vertex and Bayer partnerships introduces structural risk. Factor scores lean in the bears' direction on fundamentals: EPS momentum ranks in the 22nd to 27th percentile over 30 and 90 days, and EPS surprise ranks in the 36th percentile, reflecting a business still burning cash. Price-to-book at 3.4x has edged down slightly over the month.

Retail attention is worth noting as a separate signal. Wikipedia page views ran at a z-score of 1.6 against CRSP's own 90-day history in late September, an elevated but not extreme reading. The dataset is flagged as attention, not a revenue indicator, and there are no measured leading datasets for this company, so the signal is colour rather than a read on the upcoming print.

Institutional ownership adds one interesting layer. ARK Investment Management holds roughly 9.5 million shares, nearly 10% of the company, and reported a further purchase of 545,000 shares through September. BlackRock added 669,000 shares and State Street added 703,000 shares in the same period. Those are meaningful additions from three of the largest holders simultaneously. No 13D activists are on the register. The recent 13G activity worth flagging is Capital International, which filed in February showing its stake had fallen to 1.2% from 7.4%, a sharp reduction that reflects the kind of exit that can persist under the radar once a holder drops below the filing threshold.

CRSP's recent earnings history shows the stock can move sharply in either direction. The two most recent prints produced one-day moves of plus 5.8% and plus 10.6%, while the May release brought a 3.6% decline and an 11.4% five-day slide. The November 3 print, with the stock down roughly 6% on the month and short interest at a multi-month high, is the obvious event to watch: the question is less about Casgevy's headline numbers and more about whether the CTX310 cohort data due before year-end is large enough to shift the durability debate.